Dynamic expression analysis of peripheral blood derived small extracellular vesicle miRNAs in sepsis progression
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Xinyan Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: ICU, Dong E Hospital, Liaocheng, China. Hauptthemen laut MEDLINE: MicroRNAs, Sepsis, Extracellular Vesicles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Sepsis Translational Medicine Laboratory of Liaocheng City.
Themen: Sepsis
Abstract (Originalsprache)
Immune disorders caused by sepsis have recently drawn much attention. We sought to dynamically monitor the expression of small extracellular vesicle (sEV) miRNAs in peripheral blood during sepsis to explore these miRNAs as potential biomarkers for monitoring immune function in sepsis patients. This study included patients with sepsis. Blood samples were obtained from 10 patients on the first through 10th days, the 12th day and the 14th day since sepsis onset, resulting in 120 collected samples. Serum sEVs were extracted from peripheral venous blood, and levels of MIR497HG, miR‐195, miR‐497, and PD‐L1 in serum sEVs were detected by qPCR, and clinical information was recorded. Our study revealed that the levels of MIR497HG, miR‐195, miR‐497 and PD‐L1 in serum sEVs showed periodic changes; the time from peak to trough was approximately 4–5 days. The levels of sEV MIR497HG and miR‐195 had a positive linear relationship with SOFA score ( r values were −0.181 and −0.189; p values were 0.048 and 0.039, respectively). The recorded quantities of sEV MIR497HG, miR‐195 and PD‐L1 showed a substantial correlation with ARDS. ROC curve analysis revealed that sEV MIR497HG, miR‐195 and miR‐497 could predict the 28‐day mortality of sepsis patients with an AUC of 0.66, 0.68 and 0.72, respectively. Levels of sEVs MIR497HG, miR‐195, miR‐497 and PD‐L1 showed periodic changes with the immune status of sepsis, which provides a new exploration direction for immune function biomarkers and immunotherapy timing in sepsis patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICU, Dong E Hospital, Liaocheng, China.
- Cardiac Surgery Department, Dong E Hospital, Liaocheng, China.
- High Dependency Unit, Shandong Public Health Clinical Center, Jinan, China.
- Shandong First Medical University, Jinan, China.
- ICU, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, Jinan, China.
ORCID-Profile: Xuan Song
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Sepsis Translational Medicine Laboratory of Liaocheng City
- Shandong Provincial Postdoctoral Science Foundation
- Taishan Scholars Program of Shandong Province
Zitieren
APA
Liu, X., Yu, D., Li, T., Zhu, K., Bi, Y., Wang, C., Wang, C., & Song, X. (2024). Dynamic expression analysis of peripheral blood derived small extracellular vesicle miRNAs in sepsis progression. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18053
Vancouver
Liu X, Yu D, Li T, Zhu K, Bi Y, Wang C, et al. Dynamic expression analysis of peripheral blood derived small extracellular vesicle miRNAs in sepsis progression. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18053
BibTeX
@article{Liu2024,
author = {Liu, Xinyan and Yu, Dapeng and Li, Tiantian and Zhu, Kehan and Bi, Yang and Wang, Chaofan and Wang, Chunting and Song, Xuan},
title = {Dynamic expression analysis of peripheral blood derived small extracellular vesicle miRNAs in sepsis progression},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18053}
}
EUVIMED